| Literature DB >> 28052757 |
Serghei Malkov1, John A Shepherd2, Christopher G Scott3, Rulla M Tamimi4, Lin Ma5, Kimberly A Bertrand6, Fergus Couch3, Matthew R Jensen3, Amir P Mahmoudzadeh2, Bo Fan2, Aaron Norman3, Kathleen R Brandt3, V Shane Pankratz3, Celine M Vachon3, Karla Kerlikowske5.
Abstract
Entities:
Year: 2017 PMID: 28052757 PMCID: PMC5209878 DOI: 10.1186/s13058-016-0797-y
Source DB: PubMed Journal: Breast Cancer Res ISSN: 1465-5411 Impact factor: 6.466
Image texture features that are currently defined for all study participants
| Analysis Groups | Texture Features | Texture feature name | Reference |
|---|---|---|---|
| Gray-level Histogram | Standard deviation |
| [7, 22, 24–26] |
| Skewness |
| ||
| Kurtosis |
| ||
| Balance |
| ||
| Grey-level co-occurrence matrix (GLCM) | GLCM Energy |
| [24, 25, 27, 29] |
| GLCM Entropy |
| ||
| GLCM Dissimilarity |
| ||
| GLCM Contrast |
| ||
| GLCM Homogeneity |
| ||
| GLCM Correlation |
| ||
| GLCM Mean |
| ||
| GLCM Variance |
| ||
| Neighborhood Gray-tone Difference Matrix (NGTDM) | NGTDM Coarseness |
| [24, 28, 29] |
| NGTDM Contrast |
| ||
| NGTDM Complexity |
| ||
| NGTDM Strength |
| ||
| NGTDM Busyness |
| ||
| Edge Frequency Analysis | Mean Gradient |
| [29] |
| Fourier Transform Analysis, Power Spectrum | RMS |
| [29] |
| FMP (first moment of power spectrum) |
| ||
| SMP (second moment of power spectrum) |
| ||
| FD from power spectrum exponent |
| ||
| Fractal Analysis | Intercept of the plot of the standard deviation of the high frequency image as a function of the size the kernel |
| [29–31] |
| Continuous Dimension (CD), slope and intercept |
| ||
| HZ_PROJ |
| ||
| FD of the standard deviation |
| ||
| FD of image using thresholds from 5%-85% |
| ||
| FD of the surface of thebreast considering the gray value represent the height |
| ||
| FD, Minkowski method |
|
Risk associated of either DCIS or Invasive Cancer for each feature
| Feature | DCIS | Invasive | ER- | ER+ | ||||
|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | p-value* | p-het** | OR (95% CI) | OR (95% CI) |
| p-het** | |
| N case/control |
|
|
|
| ||||
|
| 0.87 (0.74, 1.01) | 0.87 (0.78, 0.96) | 0.010 | 0.98 | 0.84 (0.67, 1.06) | 0.88 (0.79, 0.99) | 0.048 | 0.72 |
|
| 0.88 (0.76, 1.02) | 0.88 (0.80, 0.96) | 0.011 | 0.93 | 0.85 (0.69, 1.05) | 0.86 (0.78, 0.95) | 0.009 | 0.90 |
|
| 1.18 (1.02, 1.38) | 1.13 (1.03, 1.25) | 0.010 | 0.60 | 1.16 (0.93, 1.44) | 1.15 (1.03, 1.28) | 0.024 | 0.96 |
|
| 0.85 (0.72, 1.00) | 0.87 (0.79, 0.97) | 0.015 | 0.75 | 0.84 (0.67, 1.06) | 0.89 (0.79, 1.00) | 0.085 | 0.64 |
|
| 0.90 (0.77, 1.04) | 0.89 (0.81, 0.98) | 0.034 | 0.90 | 0.85 (0.68, 1.05) | 0.89 (0.80, 1.00) | 0.066 | 0.64 |
|
| 1.19 (1.04, 1.38) | 1.09 (0.99, 1.19) | 0.022 | 0.21 | 1.03 (0.84, 1.26) | 1.06 (0.96, 1.18) | 0.479 | 0.75 |
|
| 0.86 (0.73, 1.00) | 0.90 (0.81, 0.99) | 0.032 | 0.58 | 0.98 (0.78, 1.22) | 0.91 (0.81, 1.01) | 0.216 | 0.53 |
|
| 0.84 (0.71, 0.99) | 0.89 (0.80, 0.99) | 0.035 | 0.49 | 0.83 (0.65, 1.06) | 0.91 (0.81, 1.03) | 0.170 | 0.46 |
|
| 0.90 (0.74, 1.08) | 0.86 (0.77, 0.97) | 0.042 | 0.71 | 0.77 (0.59, 1.01) | 0.89 (0.78, 1.01) | 0.063 | 0.32 |
|
| 1.15 (1.00, 1.33) | 1.09 (1.00, 1.19) | 0.053 | 0.46 | 0.92 (0.75, 1.14) | 1.09 (0.99, 1.21) | 0.128 | 0.12 |
|
| 1.05 (0.90, 1.22) | 1.13 (1.03, 1.24) | 0.042 | 0.36 | 1.06 (0.86, 1.31) | 1.12 (1.01, 1.24) | 0.091 | 0.62 |
|
| 0.96 (0.83, 1.12) | 0.89 (0.81, 0.98) | 0.057 | 0.35 | 0.95 (0.77, 1.17) | 0.89 (0.81, 0.99) | 0.110 | 0.61 |
|
| 0.85 (0.71, 1.02) | 0.9 (0.8, 1.01) | 0.077 | 0.56 | 0.9 (0.69, 1.15) | 0.92 (0.81, 1.04) | 0.348 | 0.85 |
|
| 0.92 (0.79, 1.06) | 0.91 (0.83, 1) | 0.130 | 0.98 | 0.89 (0.72, 1.09) | 0.91 (0.82, 1.01) | 0.173 | 0.77 |
|
| 1.2 (1.04, 1.39) | 1.06 (0.97, 1.16) | 0.034 | 0.09 | 0.96 (0.78, 1.18) | 1.05 (0.95, 1.16) | 0.572 | 0.43 |
Results presented as OR per 1 SD in normalized feature after adjustment for age, family history, PD, and study
*p-value refers to 2 degree of freedom to test for evidence of associated with DCIS or invasive cancer
**Heterogeneity p-value to test for differences in effect between tumor subgroups